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unpleasant after-effects associated with cannabis use. 
The pleasurable effects of cannabis use were not related 
to schizotypy score.  Conclusion: High scoring schizo-
types who use cannabis are more likely to experience 
psychotic-like phenomena at the time of use, and un-
pleasant after-effects. Our results are consistent with the 
hypothesis that cannabis use is a risk factor for full psy-
chosis in this group. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 It is accepted that the use of street drugs, including 
cannabis, increases both the risk of relapse and severity 
of symptoms in individuals already diagnosed with 
schizophrenia [e.g.  1, 2] . According to van Os et al.  [3] , 
cannabis use signiﬁ cantly increases the risk of developing 
a psychotic disorder in individuals with no previous his-
tory of illness and, additionally, predicts poor prognosis 
in those with an established vulnerability. 
 An unresolved issue is whether people who are prone 
to psychosis are drawn to cannabis use (an association 
model), or whether cannabis use truly increases the inci-
dence of psychotic experiences (a causal model) [e.g.  3–5] . 
Data from the recently reported cohort study by Arse-
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 Abstract 
 Objective: Recent studies have suggested that cannabis 
use is a risk factor for developing schizophrenia. We test-
ed the hypothesis that cannabis use increases the likeli-
hood of psychosis-like experiences in non-clinical par-
ticipants who scored highly on a measure of schizotypy. 
 Method: The psychological effects of cannabis were as-
sessed in 137 healthy individuals (76% female, mean age 
22 years) using a newly developed questionnaire con-
cerned with subjective experiences of the drug: the Can-
nabis Experiences Questionnaire. The questionnaire has 
three subscales: Pleasurable Experiences, Psychotic-like 
Experiences and After-Effects. Respondents also com-
pleted the brief Schizotypal Personality Questionnaire. 
 Results: Cannabis use was reported by 72% of the sam-
ple. Use per se was not signifi cantly related to schizo-
typy. However, high scoring schizotypes were more like-
ly to report both psychosis-like experiences and 
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nault et al.  [6] favour the causal model since cannabis use 
in adolescence appears to be a risk factor for later psycho-
sis. However results do not consistently indicate whether 
a pre-existing biological vulnerability is necessary to 
 underpin the development of psychosis in the causal 
model. 
 Researchers have frequently used self-report measures 
of schizotypy in non-clinical samples as an index of psy-
chosis-proneness, and some studies have reported that 
cannabis users have higher schizotypy scores than non-
users  [7–10] . Skosnik et al.  [11] have, for example, re-
ported that current cannabis users had higher schizotypy 
scores than either past users or those who had never used 
cannabis. Cannabis use has long been associated with an 
increase in the reporting of ‘psychosis-like’ experiences 
 [12–14] . Verdoux et al.  [15] recently explored this asso-
ciation in relation to psychosis-proneness determined by 
structured interview. Using an experience sampling 
method, researchers showed that  both degree of psychosis 
vulnerability and cannabis use were independently asso-
ciated with unusual perceptual experiences. 
 We have developed a new questionnaire (the Cannabis 
Experiences Questionnaire, CEQ) to enable cannabis us-
ers to record the various psychological effects they experi-
ence both as they smoke, and for some time after use. We 
hypothesized that: (1) cannabis use would be associated 
with higher schizotypy scores, and (2) that cannabis users 
with high schizotypy scores would report more psychosis-




 Participants were recruited on an opportunity sample basis. Our 
sample comprised 137 university students [33 (24.1%) males and 
104 (75.9%) females; average age 22.01 (SD 5.50) years]. The par-
ticipants were either completing single honours or combined stud-
ies courses which involved psychology or sociology (accounting for 
the greater numbers of females to males in this sample). Partici-




 Participants completed the brief Schizotypal Personality Ques-
tionnaire (SPQB)  [16] , a 22-item questionnaire consisting of the 
most reliable items taken from the longer Schizotypal Personality 
Questionnaire  [17] . The SPQB provides a total score and scores on 
three sub-scales: ‘disorganized’ (SPQB-D), ‘cognitive-perceptual’ 
(SPQB-CP) and ‘interpersonal’ (SPQB-I). 
 Drug Use 
 Participants were asked how often (everyday, more than once a 
week, about once a week, about once a month, a few times each 
year, about once a year, only once or twice, never) and when they 
smoked cannabis (during the morning, during the day, during the 
evening, frequently during the day and night). Information about 
other drugs used for recreational purposes was also sought. 
 Experiences with Cannabis 
 The CEQ was developed speciﬁ cally for this study to investigate 
the subjective effects of cannabis. It consists of three subscales that 
record respectively: pleasurable experiences, psychotic-like experi-
ences and after-effects. The Pleasurable Experiences subscale con-
sists of items such as: feeling happy, feeling laid back, able to un-
derstand the world better and so on  [18] . Scores on this subscale 
could range from 18 to 90. The Psychotic-Like Experiences sub-
scale comprises psychological features akin to symptoms associated 
with psychotic disorders: delusional thinking, experiencing audi-
tory hallucinations, feeling paranoid etc. [e.g.  19, 20] . For this sub-
scale scores could range from 25 to 125. The After-Effects subscale 
attempts to quantify the consequences of cannabis (after) use and 
consists of items associated with the ‘amotivational syndrome’ 
commonly reported in habitual users, e.g. loss of drive, reduced at-
tention, feeling generally slowed down and so on [e.g.  21] . Scores 
on this scale could range from 12 to 60. Participants completed the 
CEQ by indicating on a ﬁ ve-point Likert scale (Never, Occasion-
ally, Sometimes, More often than not, Always) the frequency of 
each ‘experience’ (when using cannabis). 
 Procedure 
 Respondents were asked to complete both the CEQ and the 
SPQB as fully and honestly as possible. The questionnaires were 
completed by participants in their own time (either at home or in 
the university) and returned to a labeled post box placed in a com-
munal area of the university. An anonymisation procedure ensured 
that respondents were identiﬁ able by a number only.  Data analysis 
was performed using SPSS version 11.5. Non-normally distributed 
data were transformed as appropriate. The study had full ethical 
approval as part of a larger project examining psychosis risk factors 
in a psychologically healthy population. 
 Results 
 72.5% of our sample reported having used cannabis at 
least once. For these, the frequency of use broke down as 
follows: everyday 6%, at least once a week 21%, at least 
once a month 23%, at least once a year 26%, less than 
once a year 23%. There were no gender differences in the 
rates of cannabis use. 
 Fifty-two per cent of cannabis users had used only can-
nabis. Participants who used cannabis more frequently 
(frequency use: at least once a week, a few times each 
month and about once a year) reported using more recre-
ational drugs [f(2, 95) = 4.11, p  ! 0.02]. For those who 
used cannabis once a week (n = 27) the mean number of 
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drugs used was 2.15 (SD = 2.14); for those who used can-
nabis a few times each month (n = 48): 1.23 (1.82); for 
those who had smoked cannabis about once a year (n = 
23): 0.70 (1.43). The number of additional drugs used 
varied between 1 (41% of the sample) and 10 (0.7% of the 
sample) for the whole sample. Other recreational drugs of 
choice (listed according to frequency of reporting) includ-
ed cocaine (19%), ecstasy (19%), LSD (13%), amphet-
amine (11%), magic mushrooms (7%), poppers (7%) and 
ketamine (4%). Drugs which were used by fewer than 2% 
of the participants included: solvents, GHB, nutmeg, 
benzodiazepines, MDA, opiates and barbiturates. Three 
participants who had not smoked cannabis but had used 
other drugs (LSD, cocaine and morphine) were included 
in the analyses reported below as non-cannabis users. 
 SPQB means and standard deviations (in brackets) for 
the entire sample were as follows: SPQB-CP: 3.03 (2.10), 
SPQB-I: 2.65 (2.33), SPQB-D: 1.82 (1.76) and for the 
SPQB total score 7.50 (4.71). The distribution of the 
SPQB total score approximated to normal but each of the 
subscales required (logarithmic) transformation prior to 
statistical analysis. There were no signiﬁ cant differences 
between those who reported having used cannabis and 
those who had not on the SPQB total or any of the SPQB 
subscales. 
 Relationship between SPQ-B Scores and CEQ 
Subscales 
 In the sample who reported ever using cannabis (n = 
99, 72%) the means for the subscales from the CEQ were 
as follows: Pleasurable Experiences 39.94 (9.94), Psychot-
ic-Like Experiences 43.12 (12.98) and After-Effects 22.71 
(9.31). In each case, distribution of data was approxi-
mately normal. Bivariate correlational analyses were per-
formed in line with the study hypotheses indicating sig-
niﬁ cant positive correlations between the Psychotic-Like 
Experiences subscale and the SPQB-D subscale (r = 0.40, 
p  ! 0.01), the SPQB-CP subscale (r = 0.33, p  ! 0.01) and 
the SPQB total score (r = 0.44, p  ! 0.01). The After-Ef-
fects subscale was also correlated with the SPQB-D sub-
scale (r = 0.35, p  ! 0.01), the SPQB-P subscale (r = 0.47, 
p  ! 0.01) and the SPQB total score (r = 0.49, p  ! 0.01). 
The Pleasurable Experiences subscale was not signiﬁ cant-
ly correlated with any SPQB scores. 
 There were 51 participants who had used only canna-
bis. When the correlational analysis was restricted to only 
these participants the results remained largely similar to 
those reported above. There were positive correlations 
between the Psychotic-Like Experiences subscale and the 
SPQB-CP (r = 0.30, p  ! 0.05), the SPQB-D (r = 0.40, p  ! 
0.01) and the SPQB total (r = 0.38, p  ! 0.01). The After-
Effects subscale was also correlated with the SPQB-CP
(r = 0.44, p  ! 0.01) and the SPQB total (r = 0.39, p  ! 0.01). 
 
 Discussion 
 This paper reports on the concurrent and subsequent 
effects of recreational cannabis use in a sample of healthy 
respondents using a newly developed scale (the CEQ) to 
examine subjective experiences. The modest sample size 
in this exploratory study was partly compensated for by 
the high rate of reported cannabis use (72%). The CEQ 
appears to be an acceptable and useful instrument which 
generates quantitative data about subjective experiences. 
 Unlike previous research  [7–11] we did not ﬁ nd that 
cannabis users had higher schizotypy scores than non-us-
ers. In our sample at least, it seems that schizotypal traits 
do not predispose young people to smoke cannabis, nor 
does cannabis use, per se, elevate schizotypy scores. It 
may be that this ‘failure to replicate’ is partly a conse-
quence of the high rates of reported cannabis use in our 
sample: Verdoux et al.  [15] found considerably lower 
rates of recent or current drug use in their French cohort, 
for example. However, the main hypotheses were con-
ﬁ rmed in that amongst individuals who smoked (or had 
ever smoked) cannabis, high schizotypy was associated 
with a greater likelihood of experiencing both psychotic-
like features during drug use and unpleasant after-effects. 
Pleasurable experiences, on the other hand, were equally 
reported across the sample and apparently unrelated to 
schizotypy score. 
 Despite the comparatively high rate of cannabis use in 
our sample, the increased reporting of psychosis-like ex-
periences in cannabis users with high schizotypy scores 
broadly supports the ﬁ ndings of Verdoux et al.  [15] . Tak-
en together, both sets of results suggest that those most 
prone to psychosis, whilst experiencing similar levels of 
the pleasurable experiences of cannabis as other respon-
dents, are more likely to additionally experience psychot-
ic-like experiences and after-effects. 
 A limitation of the current study is that participants 
were not screened for the presence of psychiatric illnesses. 
The collection of the data in this study did not permit fol-
low-up which would have presented the opportunity for a 
screening tool to be used. Similarly, a family history of 
psychiatric illness may impact upon participants’ experi-
ences during cannabis use, assuming that a biological in-
dividual difference mediates cannabis response. The data 
were collected from students, some of whom were known 
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to the researchers; therefore every effort was made to per-
mit complete anonymity for the participants, and this to 
some extent restricted the data which could be collected. 
 Individuals who have high schizotypy scores and who 
report psychotic-like responses to cannabis may represent 
a particularly high risk group for psychosis. Delta-9-tet-
rahydrocannabinol is the principle active ingredient in 
cannabis  [22] . In humans, it binds to cannabinoid (CB1) 
receptors localized in the prefrontal cortex, basal ganglia 
and hippocampus  [23] where it has a dopamine agonist 
action  [24, 25] . The heightened sensitivity of dopamine 
systems observed in acute schizophrenia  [26] may also be 
present to some degree along the psychosis continuum 
[e.g.  27] . This would explain why high scoring schizotypes 
who use cannabis are more likely to have psychosis-like 
experiences and pronounced after-effects than their low 
scoring counterparts. There is an overlap in the charac-
teristics of schizotypal personality, in particular the posi-
tive aspects (e.g. unusual perceptual experiences) and 
possible responses to recreational drug use. However, 
Verdoux et al.  [13] have shown that psychosis proneness 
does inﬂ uence people’s experiences for a time following 
cannabis use, lending some support to the notion that in-
dividual differences in response to cannabis may be re-
lated to psychosis proneness. Perhaps individuals who 
have many features of the schizotypal trait prior to can-
nabis use experience psychotic-like responses to cannabis 
use as well as more after-effects, leading to an increase in 
both the negative and positive aspects of schizotypy. 
However, those who do not have schizotypal characteris-
tics only experience the unusual perceptual experiences 
commonly reported during cannabis use and do not have 
the ‘amotivational’ after-effects. This would mean only 
the positive aspects of schizotypy would increase. Testing 
such a hypothesis would require a longitudinal study in-
volving adolescents prior to their exposure to cannabis 
and it may shed some further light on the relationship 
between cannabis and psychotic symptoms. 
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